XNYS · Healthcare · Diagnostics & Research
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
Agilent posted a solid beat in diagnostics and research, with **$1.62 EPS** and **$1.9B revenue** topping estimates; the modest mid-single-digit sales growth suggests steady execution, not a breakout. Guidance of **$5.90-$6.04 EPS** and **$7.3B-$7.5B revenue** looks conservative but credible.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-26 | Q3 2026 | 1.48 | 1.62 | +9.46% | $1.88B | ✅ Beat | +3.20% | — | — |
| 2026-05-27 | Q2 2026 | 1.41 | 1.49 | +5.67% | $1.83B | ✅ Beat | +7.91% | +18.61% | +17.41% |
| 2026-02-25 |
| Q1 2026 |
| 1.37 |
| 1.36 |
| -0.73% |
| $1.80B |
| ❌ Miss |
| -2.98% |
| -3.35% |
| -11.61% |
| 2025-11-24 | Q4 2025 | 1.59 | 1.59 | +0.00% | $1.86B | ➖ Inline | — | — | — |
| 2025-08-27 | Q3 2025 | 1.36 | 1.37 | +0.74% | $1.74B | ✅ Beat | — | — | — |
| 2025-02-26 | Q1 2025 | 1.27 | 1.31 | +3.15% | $1.68B | ✅ Beat | -5.50% | -5.92% | -13.22% |
| 2024-11-25 | Q4 2024 | 1.40 | 1.46 | +4.29% | $1.70B | ✅ Beat | -0.09% | +3.78% | +1.00% |
| 2024-08-21 | Q3 2024 | 1.26 | 1.32 | +4.76% | $1.58B | ✅ Beat | +0.16% | +0.76% | +0.07% |
Showing last 8 quarters.